Live News Categoriesmarket

IMCR.O (IMCR.O) News

Follow IMCR.O (IMCR.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol IMCR.O Asset market Sector Markets 90 days 1 Updated Oct 15, 2026, 11:07 AM UTC Open live news feed

L Immunocore doses first patient in Phase 1 trial of IMC — S118AI for type 1 diabetes Immunocore dosed the first patient in a Phase 1 trial of IMC-S118AI, its first autoimmune disease candidate, for type 1 diabetes. The dose-escalation study will evaluate safety, pharmacokinetics and clinical activity in NEWS | Oct 15, 2026, 11:07 AM UTC